Reproductive Biology and Endocrinology

Reproductive Biology and Endocrinology is an open-access journal published by BMC, part of Springer Nature, which was launched in 2003 and covers human reproductive biology and endocrinology from gametogenesis to assisted reproduction and clinical reproductive medicine, with a 2025 Journal Impact Factor of 5.7.《生殖生物学与内分泌学》（Reproductive Biology and Endocrinology）由（BMC）出版，隶属（Springer Nature），2003 年创刊，覆盖从配子发生到辅助生殖与临床生殖医学的人类生殖生物学与内分泌学，2025 年期刊影响因子为 5.7。

Scope

• Gametogenesis, fertilisation and early embryonic development are central subjects, treated at the level of mechanism rather than description.配子发生、受精与早期胚胎发育是核心选题，且要求落到机制层面而非现象描述。
• Embryo-uterine interaction, implantation and endometrial biology form a second cluster.胚胎与子宫的相互作用、着床以及子宫内膜生物学构成第二个集群。
• Reproductive development and reproductive ageing are covered, including the decline of ovarian and testicular function.生殖发育与生殖衰老亦在范围内，包括卵巢与睾丸功能的衰退。
• Endocrine regulation of reproduction, the hypothalamic-pituitary-gonadal axis, neuroendocrinology and hormonal signalling are treated in depth.生殖的内分泌调控、下丘脑—垂体—性腺轴、神经内分泌与激素信号均作深入处理。
• The mechanisms of female and male infertility are a standing priority, as are assisted reproductive technologies, embryology and reproductive interventions.女性与男性不孕的机制是长期重点，辅助生殖技术、胚胎学与生殖干预同样如此。
• Reproductive disorders such as polycystic ovary syndrome, endometriosis, implantation failure and pregnancy loss are regularly considered.多囊卵巢综合征、子宫内膜异位症、着床失败与妊娠丢失等生殖疾病属常规选题。
• Immunological, metabolic and microenvironmental regulation of reproductive function is welcomed, including translational and clinically relevant multi-omics studies.生殖功能的免疫、代谢与微环境调控亦受欢迎，包括具转化价值与临床意义的多组学研究。

History

• The journal was conceived in the spring of 2002 by reproductive scientists who saw a gap in electronic publishing, and Antonin Bukovsky, its initiator, was elected founding editor-in-chief by the board.本刊由一批生殖科学家于 2002 年春酝酿，起因是当时电子出版存在空白，发起人 Antonin Bukovsky 经编委会选举出任首任主编。
• It launched in January 2003 with twenty research articles already accepted, each having passed a two- or three-stage review by three experts.2003 年 1 月创刊时已有二十篇研究论文被接受，每篇均经三位专家两到三轮评审。
• BioMed Central of London was the original publisher, and the title moved with BMC into Springer Nature, with content now hosted on Springer Nature Link.原出版方为伦敦的（BioMed Central），本刊随（BMC）并入（Springer Nature），内容现托管于（Springer Nature Link）。
• From the first volume the journal was fully open access, financed by article processing charges rather than subscriptions.自首卷起本刊即为完全开放获取，经费来自文章处理费而非订阅。
• Articles are published continuously and identified by article numbers, so Volume 1 opened with article 1 in January 2003.论文连续出版并以文章编号标识，故第 1 卷以 2003 年 1 月的第 1 号文章开篇。
• The 2025 Journal Impact Factor is 5.7, after 4.7 in 2024, 4.982 in 2022 and 5.211 in 2021, ranking fifth of forty-four titles in reproductive biology.2025 年期刊影响因子为 5.7，2024 年为 4.7，2022 年为 4.982，2021 年为 5.211，在生殖生物学类 44 种期刊中位列第五。

Editors

• Raoul Orvieto of the Sheba Medical Center in Israel is co-editor-in-chief, a professor of obstetrics and gynaecology at Tel Aviv University who works on controlled ovarian stimulation and the prevention of ovarian hyperstimulation syndrome.以色列（Sheba Medical Center）的 Raoul Orvieto 为共同主编，兼任特拉维夫大学妇产科学教授，研究控制性卵巢刺激与卵巢过度刺激综合征的预防。
• David B. Seifer of Yale School of Medicine is the other co-editor-in-chief, known for work on ovarian ageing, anti-Mullerian hormone and inhibin B in assisted reproduction.耶鲁大学医学院的 David B. Seifer 为另一位共同主编，以卵巢衰老及抗苗勒管激素、抑制素 B 在辅助生殖中的应用研究著称。
• Twenty-two section editors cover the journal's subject areas and are drawn from Israel, the United States, China, Italy, Greece, India, Denmark, Spain, Canada and Hong Kong.二十二位栏目编辑覆盖各学科方向，分别来自以色列、美国、中国、意大利、希腊、印度、丹麦、西班牙、加拿大与中国香港。
• The wider editorial board numbers about forty members, including Ashok Agarwal of the Cleveland Clinic and Norbert Gleicher of the Center for Human Reproduction in New York.更广泛的编委会约四十人，包括克利夫兰医学中心的 Ashok Agarwal 与纽约人类生殖中心的 Norbert Gleicher。
• Manuscripts are assigned by subject to a section editor under the two editors-in-chief, and the journal states that reviewer reports should be constructive and aimed at improving the paper.稿件按学科由共同主编分派给栏目编辑，期刊明确要求审稿意见具建设性并以改进论文为目的。
• Original research and reviews are both considered, with preference for studies that link fundamental biology to translational and clinical application in reproductive health and disease.原创研究与综述均在考虑之列，并优先发表把基础生物学与生殖健康及疾病的转化和临床应用相衔接的研究。